News

Serina Therapeutics Updates on SER-252 Development Progress

Serina Therapeutics Updates on SER-252 Development Progress

Serina Therapeutics Provides Update on SER-252 Development

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a biotechnology firm focusing on innovative drug optimization technologies, has recently introduced key updates on its SER-252 program designed for advanced Parkinson's disease. The U.S. Food and Drug Administration (FDA) has placed the Company’s Investigational New Drug (IND) application on clinical hold as it requests additional information related to specific components in the formulation. It is essential to note that the FDA's feedback pertains only to a common excipient and not the active drug itself or its mechanism of action.

Regulatory Actions and Next Steps

Moving forward, Serina plans to collaborate closely with the FDA to ensure all concerns are promptly addressed. The company anticipates formally receiving the clinical hold letter from the FDA within the next few weeks. In previous discussions, the FDA expressed support for Serina's development approach for SER-252 under the 505(b)(2) New Drug Application pathway, a route that offers a streamlined process for certain applications.

CEO’s Commitment to the Program

Steve Ledger, the Chief Executive Officer of Serina, expressed his appreciation for the FDA’s constructive engagement, stating, "We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252. Importantly, the feedback does not relate to the underlying drug candidate or its intended mechanism, and we continue to believe strongly in the potential of SER-252 to improve treatment options for people living with advanced Parkinson's disease.”

Support and Confidence from Leadership

Greg Bailey, MD, a Board Member of Serina and Executive Chairman of Juvenescence, reiterated his commitment to Serina, indicating his support extends both financially and strategically. He emphasized that receiving regulatory feedback is a normal part of responsible drug development and expressed confidence in the team’s ability to address the FDA’s comments. The leadership confidence remains robust regarding the long-term potential for SER-252 to enhance the lives of those affected by Parkinson's disease.

Continued Innovation with the POZ Platform

In addition to SER-252, Serina remains dedicated to advancing its broader pipeline based on the proprietary POZ Platform technology. This includes SER-270, a once-weekly injectable treatment aimed at tardive dyskinesia (TD), along with other innovations in their POZ-LNP, POZ-ADC, and POZ-AOC technology. These platforms are designed to enhance drug efficacy and patient experience across a variety of therapeutic applications.

Study Design Overview for SER-252

The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b clinical trial comprising both single and multiple ascending dose components, which will include 40 participants in their initial phase. This trial aims to assess safety, tolerability, and pharmacokinetics for subcutaneous SER-252 versus placebo while measuring efficacy through various motor functionality assessments.

Understanding SER-252 and Its Mechanism

SER-252 is an investigational therapy based on apomorphine, leveraging the capacity of the POZ platform to deliver consistent dopaminergic stimulation through easy-to-administer subcutaneous injections. The innovative design aims to manage motor fluctuations effectively, particularly for advanced Parkinson's patients, thus improving their daily living and reducing off-time and related complications.

What Sets the POZ Platform Apart

Serina’s POZ technology utilizes a synthetic water-soluble polymer, facilitating more accurate drug loading and release rates during subcutaneous administration. The approach aims to lower adverse effects associated with peak-trough variations in medication levels, enhancing patient outcomes significantly. This advanced drug delivery technology holds promise for broader applications beyond current indications.

About Serina Therapeutics

Serina is at the forefront of biotechnological innovation, dedicated to developing a robust pipeline of therapies targeting various neurological conditions and other health challenges. Located in Huntsville, Alabama, Serina the POZ Platform to enhance the efficacy and safety profiles of multiple therapeutic modalities—including small molecules and antibody-drug conjugates—showcases its commitment to improving patient care. For more details on Serina’s work and innovations, visit their official website.

Frequently Asked Questions

What was the FDA's recent action regarding SER-252?

The FDA placed a clinical hold on SER-252's IND application, requesting additional information about a formulation component.

How does SER-252 aim to help Parkinson’s disease patients?

SER-252 is designed to provide continuous dopaminergic stimulation, helping to manage motor fluctuations and improve daily living for Parkinson's patients.

Who is leading Serina Therapeutics?

Steve Ledger serves as the Chief Executive Officer, guiding the company’s strategic direction and initiatives.

What is the POZ Platform?

Serina's POZ Platform is drug optimization technology focusing on precision in drug delivery to enhance therapeutic efficacy and minimize side effects.

What are the next steps for Serina regarding FDA feedback?

Serina intends to collaborate proactively with the FDA to address the feedback and align on the next steps for the clinical program.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 169

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 82

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 46

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 22

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 69

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 189

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 150

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Edward H. McKay Takes Helm as New CEO of Shenandoah Telecommunications

Updated Category News Views 218

Leadership Change at Shenandoah Telecommunications Shenandoah Telecommunications Company, often referred to as "Shentel," has officially announced a significant leadership transition. Edward H. "Ed" McKay has been appointed as the new President and Chief Executive Officer. This change is set to take place on a specified date in the near future, as current President and...

Continue Reading
Projected Growth of Security Printing Market to USD 5.79 Billion

Updated Category News Views 118

Security Printing Market Overview SkyQuest has forecasted that the global security printing market will achieve a remarkable valuation of USD 5.79 billion by the year 2031. This represents a compound annual growth rate (CAGR) of 3.10% during the projection period, which spans from 2024 to 2031. The driving force behind this growth is the collective efforts of governments...

Continue Reading
Prosperity Bancshares, Inc. and Southwest Bancshares Unite

Updated Category News Views 136

Prosperity Bancshares, Inc. Merges with Southwest Bancshares In an exciting development for the banking sector, Prosperity Bancshares, Inc. has officially completed its merger with Southwest Bancshares, Inc. This strategic consolidation promises to bring enhanced customer service and a richer array of financial products, benefiting customers in various ways. As the...

Continue Reading
Revolutionizing AI Security Standards: Wallarm's A2AS Framework

Updated Category News Views 970

Wallarm's Role in Advancing AI Security Today, Wallarm announced its significant contribution to the release of "A2AS: Agentic AI Runtime Security and Self-Defense." This innovative project, spearheaded by Eugene Neelou, aligns various industry leaders, including AWS, Cisco, Google, and more, to fortify the foundation of AI security protocols. The A2AS Framework: A New...

Continue Reading
R2 Wireless Expands Operations with New US Leadership Team

Updated Category News Views 355

R2 Wireless Expands Operations with New Leadership R2 has made a significant stride in addressing the increasing threats and advancements in Electronic Warfare and Counter-UAS programs. The company has launched its US operations and appointed Mr. Cordell Bennigson as its US CEO. Strategic Move for Growth This strategic decision comes in response to the rising global...

Continue Reading